Bristol-Myers Squibb Company BMY

BMY Company Overview

Bristol-Myers Squibb Company (NYSE: BMY) is a global biopharmaceutical company focused on discovering, developing, licensing, manufacturing, and commercializing prescription medicines for serious diseases. The company primarily operates in the pharmaceutical and biotechnology industries, with major therapeutic focus areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience. Its core revenue drivers include innovative branded medicines such as Opdivo, Eliquis, Revlimid, Pomalyst, Yervoy, and Reblozyl, along with a growing portfolio of cell therapies and specialty biologics. Bristol-Myers Squibb serves hospitals, physicians, specialty pharmacies, government healthcare systems, and patients across developed and emerging healthcare markets.

The company traces its origins to the 1887 founding of Bristol, Myers Company and later evolved through mergers and acquisitions, most notably the 1989 merger that formed Bristol-Myers Squibb and the 2019 acquisition of Celgene Corporation, which significantly expanded its oncology and hematology portfolio. Bristol-Myers Squibb has positioned itself as a leader in immuno-oncology and specialty therapeutics through extensive research capabilities, global commercialization infrastructure, and strategic acquisitions. Its competitive positioning is strengthened by a diversified late-stage pipeline, established regulatory expertise, and significant intellectual property assets supporting high-value biologic and specialty drug franchises.